Auxier Asset Management held its position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,899 shares of the biopharmaceutical company’s stock at the end of the second quarter. Auxier Asset Management’s holdings in Pfizer were worth $3,025,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Oliver Luxxe Assets LLC raised its stake in shares of Pfizer by 429.0% in the first quarter. Oliver Luxxe Assets LLC now owns 100,305 shares of the biopharmaceutical company’s stock valued at $2,973,000 after buying an additional 81,343 shares during the last quarter. Howard Capital Management raised its stake in shares of Pfizer by 1.4% in the first quarter. Howard Capital Management now owns 85,190 shares of the biopharmaceutical company’s stock valued at $2,525,000 after buying an additional 1,162 shares during the last quarter. Montrusco Bolton Investments Inc. raised its stake in shares of Pfizer by 32.2% in the first quarter. Montrusco Bolton Investments Inc. now owns 14,769 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 3,599 shares during the last quarter. Dividend Asset Capital LLC raised its stake in shares of Pfizer by 31.5% in the first quarter. Dividend Asset Capital LLC now owns 13,844 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,315 shares during the last quarter. Finally, V Wealth Management LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $272,000. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.402% during trading on Monday, hitting $33.695. The stock had a trading volume of 7,889,692 shares. The company’s 50-day moving average is $34.29 and its 200 day moving average is $34.19. The firm has a market cap of $204.38 billion, a PE ratio of 29.871 and a beta of 0.86. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period last year, the business earned $0.56 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Several equities research analysts recently commented on the stock. Argus reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Jefferies Group reissued a “buy” rating and issued a $42.00 target price (up previously from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 target price for the company. in a research note on Tuesday, June 28th. Finally, Citigroup Inc. reissued a “neutral” rating and issued a $37.00 target price on shares of Pfizer in a research note on Wednesday, August 3rd. Ten equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.